Advertisement

Topics

BMS’ Opdivo fails late-stage brain cancer test

04:55 EDT 10 May 2019 | pharmaphorum

Bristol-Myers Squibb has run into yet another hurdle trying to extend the use of its immuno-oncology blockbuster Opdivo into new types of cancer. The latest setback for the PD-1 inhibitor comes in a phase 3 trial of the drug alongside radiotherapy...

Original Article: BMS’ Opdivo fails late-stage brain cancer test

NEXT ARTICLE

More From BioPortfolio on "BMS’ Opdivo fails late-stage brain cancer test"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...